Artivion (AORT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.13
- Estimate
- $0.10
- Surprise
- +34.5%
- Score at report (before → after)
- 6.2 → 6.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Artivion (AORT) beat the $0.10 estimate with adjusted EPS of $0.13 — a large 34.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.2/10) to Hold at 6.0/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AORT Sell at 5.3/10.
1 of the last 4 quarters beat the estimate; this quarter's +34.5% surprise compares with a +4.3% four-quarter average. Next scheduled report: 2027-02-11.
What argues against it
- Concentration risk — Supplier: Endospan (NEXUS family)
- Concentration risk — Supplier: AMDS sole manufacturer
- Quality below floor (4.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.47
- Price target
- $33.47
- Stop
- $17.57
- Upside to target
- +81.2%
- Reward-to-risk
- 5.4:1
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
AORT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $931.9M
- P/E (fwd)
- 36.7
- 52-week range
- $18.95–$48.25
- Off 52-week high
- 61.7%
- RSI (14)
- 34
- Volume vs avg
- 0.64×
- Score today
- 5.3/10